Innova Biosciences boosts Lightning-Link antibody labelling tech

The Lightning-Link platform – marketed by Innova Biosciences – is now available in volumes from 10µg to 100mg in single reaction vials.

“For antibody manufacturers that have fixed internal processes for conjugation, bulk supply of ultra-high quality raw materials and labels that are used in the Lightning-Link kits are also available,” ​said the firm.

The platform can be used in research & development (R&D) and drug discovery, and according to Innova Biosciences is the most efficient method of labelling antibodies or proteins on the market – with only 30 seconds hands-on time.

CEO Alastair Carrington said the extended capabilities will benefit both small and large-scale antibody manufacturers. 

“Access to Lightning-Link technology will enable manufacturers to dramatically increase their conjugate portfolios, whilst retaining batch-to-batch consistency,” ​he added.

Last month, US Biological announced​ an antibody labelling deal with Innova Biosciences’ Lightning-Link technology.